Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Phase 2 Recruiting
200 enrolled
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
Recruiting
2,415 enrolled
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Phase 2 Recruiting
60 enrolled
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
Phase 2 Recruiting
286 enrolled
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
Recruiting
6,035 enrolled
MK-9999-01A
Phase 1/2 Recruiting
90 enrolled
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Phase 1/2 Recruiting
27 enrolled
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
Phase 2 Recruiting
94 enrolled
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Phase 1/2 Recruiting
289 enrolled
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Phase 2 Recruiting
98 enrolled
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Phase 1/2 Recruiting
104 enrolled
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Phase 3 Recruiting
750 enrolled
A Study of Avutometinib for People With Solid Tumor Cancers
Phase 1 Recruiting
23 enrolled
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Phase 1/2 Recruiting
147 enrolled
PEDS-PLAN
Phase 2 Recruiting
500 enrolled
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Phase 2 Recruiting
122 enrolled 2 FDA
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
Phase 1 Recruiting
34 enrolled
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Phase 2 Recruiting
45 enrolled
RISE in HR NBL
Phase NA Recruiting
84 enrolled
GLOW-FISH
Phase 1/2 Recruiting
22 enrolled
SJFAMILY
Recruiting
1,500 enrolled
18F-DOPA II - PET Imaging Optimization
Phase 3 Recruiting
800 enrolled
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Phase 1/2 Recruiting
90 enrolled
SPEARHEAD-3 Pediatric Study
Phase 1/2 Recruiting
20 enrolled
Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/IIļ¼Multi-center, Clinical Study.
Phase 1/2 Recruiting
125 enrolled
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Phase 2 Recruiting
131 enrolled
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Phase 2 Recruiting
93 enrolled
NB-NK-2026
Phase 3 Recruiting
5 enrolled
SABRE
Phase 1 Recruiting
18 enrolled
BRICCS
Recruiting
40 enrolled
NMTT
Phase 2 Recruiting
441 enrolled
Phase II Study of Proton Radiation Therapy for Neuroblastoma
Phase NA Recruiting
30 enrolled
GPC2
Phase 1 Recruiting
45 enrolled
Aflac-NBL-2002
Phase 1 Recruiting
24 enrolled
Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
Phase 1/2 Recruiting
42 enrolled
PHOX2B
Phase 1 Recruiting
38 enrolled
Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma
Phase NA Recruiting
30 enrolled
NEUROBLU 02
Phase 1 Recruiting
18 enrolled
MAST
Recruiting
1,000 enrolled
Indocyanine Green (ICG) Guided Tumor Resection
Phase 1 Recruiting
230 enrolled
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Phase 2 Recruiting
62 enrolled
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Phase 1 Recruiting
32 enrolled
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
Phase 2 Recruiting
12 enrolled
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
Phase 1 Recruiting
22 enrolled
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
Recruiting
2,070 enrolled
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Phase 1/2 Recruiting
3 enrolled
Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma
Recruiting
30 enrolled
Flavored, Oral Irinotecan VAL-413 (OrotecanĀ®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Phase 1 Recruiting
20 enrolled
GINAKIT2
Phase 1 Recruiting
70 enrolled
Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
Phase 1 Recruiting
18 enrolled